| Effects of growth reduction therapy using high-dose 17beta-estradiol in 26 constitutionally tall girls. | |
| | |
MedLine Citation:
|
PMID: 16584515 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The efficacy and safety of height-limiting therapy with high-dose 17beta-oestradiol in girls with constitutionally tall stature (CTS) are controversial. We evaluated the effectiveness of high-dose 17beta-oestradiol in premenarchal girls with CTS treated until their bone age reached 14 years. DESIGN: We retrospectively reviewed the medical records of the girls managed between 1989 and 2000 with high-dose 17beta-estradiol for CTS with a predicted final height greater than +3SDs. PATIENTS: Twenty-six girls met our inclusion criteria. At baseline, mean chronological age was 12.06 +/- 1.51 years and mean height was 171.1 +/- 6.5 cm with a height standard deviation score of 4.5 +/- 0.24, and mean predicted final height was 183.0 +/- 4.2 cm. Treatment was stopped when bone age reached 14 years; mean treatment duration was 1.62 +/- 0.76 years. MEASUREMENTS: The following were obtained at 6-month intervals: height, body weight, Tanner stage, bone age, plasma cholesterol and triglycerides, plasma glucose and side effects. A mailed questionnaire on final height and satisfaction was sent 2 years after treatment discontinuation (response rate, 24/26). Results Final height was significantly (P < 0.001) reduced, by 2.4 +/- 3.2 cm, as compared to predictions. High-dose 17beta-estradiol therapy decreased growth velocity and significantly increased skeletal maturation (P < 0.001). Linear growth after treatment discontinuation was 3.3 +/- 1.9 cm. No serious side effects were recorded. Most of the patients were satisfied with the treatment. CONCLUSION: High-dose 17beta-estradiol was moderately effective in reducing final height and should probably be reserved for selected patients, particularly as knowledge on potential long-term side effects is lacking. |
| | |
Authors:
|
U Radivojevic; E Thibaud; D Samara-Boustani; C Duflos; M Polak |
Related Documents
:
|
10560995 - Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for th... 1461825 - Long-term treatment with 1 alpha-hydroxyvitamin d3 with calcium supplement in spinal os... 1056285 - Effect of salmon calcitonin on cardiac output, oxygen transport and bone turnover in pa... 15682845 - Quantitative three-phase bone scintigraphy in the evaluation of intravenous regional bl... 20003875 - New radiographic parameters assessing forefoot abduction in the adult acquired flatfoot... 22434095 - Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocatio... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical endocrinology Volume: 64 ISSN: 0300-0664 ISO Abbreviation: Clin. Endocrinol. (Oxf) Publication Date: 2006 Apr |
Date Detail:
|
Created Date: 2006-04-04 Completed Date: 2006-07-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0346653 Medline TA: Clin Endocrinol (Oxf) Country: England |
Other Details:
|
Languages: eng Pagination: 423-8 Citation Subset: IM |
Affiliation:
|
Department of Paediatric Endocrinology and Gynaecology, Necker-Enfants Malades Hospital, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Analysis of Variance Body Height / drug effects Child Depression, Chemical Drug Administration Schedule Estradiol / administration & dosage*, therapeutic use Female Growth Disorders / drug therapy*, psychology Humans Patient Satisfaction Retrospective Studies Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
50-28-2/Estradiol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phenotypic variability in children with growth hormone deficiency associated with posterior pituitar...
Next Document: A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in...